Effectiveness of Personal Protective Equipment for Healthcare Workers Caring for Patients with Filovirus Disease: A Rapid Review

Mona Hersi1*, Adrienne Stevens1,2*, Pauline Quach1, Candyce Hamel1, Kednapa Thavorn1,3, Chantelle Garrity1,2, Becky Skidmore4, Constanza Vallenas5, Susan L. Norris5, Matthias Egger6,7, Sergey Eremin5, Mauricio Ferri8, Nahoko Shindo5, David Moher1,3

1 Clinical Epidemiology Program, Centre for Practice-Changing Research, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada, 2 TRIBE graduate program, University of Split School of Medicine, Split, Croatia, 3 School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada, 4 Independent Consultant, Ottawa, Ontario, Canada, 5 World Health Organization, Geneva, Switzerland, 6 Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, 7 Centre for Infectious Disease Epidemiology and Research, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa, 8 Department of Community Health Sciences, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada

* These authors contributed equally to this work.

Abstract

Background

A rapid review, guided by a protocol, was conducted to inform development of the World Health Organization’s guideline on personal protective equipment in the context of the ongoing (2013–present) Western African filovirus disease outbreak, with a focus on health care workers directly caring for patients with Ebola or Marburg virus diseases.

Methods

Electronic databases and grey literature sources were searched. Eligibility criteria initially included comparative studies on Ebola and Marburg virus diseases reported in English or French, but criteria were expanded to studies on other viral hemorrhagic fevers and non-comparative designs due to the paucity of studies. After title and abstract screening (two people to exclude), full-text reports of potentially relevant articles were assessed in duplicate. Fifty-seven percent of extraction information was verified. The Grading of Recommendations Assessment, Development and Evaluation framework was used to inform the quality of evidence assessments.
Results
Thirty non-comparative studies (8 related to Ebola virus disease) were located, and 27 provided data on viral transmission. Reporting of personal protective equipment components and infection prevention and control protocols was generally poor.

Conclusions
Insufficient evidence exists to draw conclusions regarding the comparative effectiveness of various types of personal protective equipment. Additional research is urgently needed to determine optimal PPE for health care workers caring for patients with filovirus.

Introduction
The family Filoviridae includes three genera, Cuevavirus, Ebolavirus, and Marburgvirus. Four ebolaviruses (Bundibugyo virus, Ebola virus, Sudan virus, and Tai Forest virus) cause Ebola virus disease (EVD) and two maburgviruses (Marburg virus and Ravn virus) cause Marburg virus disease (MVD) [1]. EVD and MVD are severe illnesses in humans, with a combined mean case fatality rate of 55.4% [2]. The natural hosts of the filoviruses are unknown but fruit bats have been implicated in the transmission of Marburg virus and Ravn virus [3,4]. The majority of cases in an outbreak become infected from direct contact through non-intact skin or mucous membranes with the bodily fluids of infected symptomatic persons or the body of deceased persons. Airborne transmission of filoviruses has not been documented in humans [5,6]. The incubation period for both filovirus diseases is in the range of 2 to 21 days [7,8]. Patients are infectious once they start to exhibit symptoms which include sudden onset fever, fatigue, headaches and muscle pain followed by diarrhea, vomiting, and lethargy [7–9]. EVD patients frequently experience severe dehydration, kidney and liver dysfunction [7]. Patients of both diseases may experience internal and external bleeding in the later course of the disease, around 5–7 days [7,8,10]. Although different diseases, EVD and Marburg virus disease (MVD) have similar presentations, case fatality rate, and transmission mechanism. Both have no specific treatment to date.

Outbreaks of EVD have occurred since 1976. A rapidly evolving outbreak that has presumed to have emerged in December 2013 [11], and is ongoing as of the date of publication of this manuscript, has yielded the highest number of cases and deaths. As of 30 August 2015, 11290 deaths have occurred from among 28073 confirmed, probable, and suspected cases reported from countries most affected by the outbreak, namely, Guinea, Liberia, and Sierra Leone [12]. When infection prevention and control (IPC) measures are inadequate, there is a high risk of transmission to healthcare workers (HCWs) treating those with suspected or known filovirus infection. In the three most affected countries, a total of 513 reported deaths have occurred as of 30 August 2015 among 881 HCWs known to have been infected with EVD [12]. Inadequate source control, insufficient training on appropriate IPC practices, shortages of personal protective equipment (PPE) and improper PPE use, long working hours in the face of a shortage of medical personnel, and transmission outside the patient care setting are possible explanations [12,13].

Specifications for the components of PPE to be worn during delivery of care are important, not only to reduce the likelihood of transmission to HCWs from a barrier standpoint but to also ensure comfort and safety as wearing PPE increases the risk of heat stress and the loss of
dexterity [14,15]. The PPE worn should also allow for the best possible care to patients. Currently, PPE recommendations and protocols differ across organizations responding to the outbreak, including the World Health Organization (WHO) and Médecins Sans Frontières (MSF) [16,17].

WHO issued recommendations on PPE for use by HCWs managing patients with known or suspected filovirus disease in October 2014 [17]. To inform these recommendations, we performed a rapid review of the evidence on the effectiveness of different types of PPE in preventing ebolavirus transmission and on levels of dexterity and discomfort, for example, comparing gowns versus coveralls or comparing single versus doubles gloves.

**Methods**

We performed a "rapid review", a type of review produced using accelerated and/or modified systematic review methods in order to accommodate an expedited turnaround time [18]. The rapid review was conducted over a 7-week period from 28 July to 12 September 2014. This rapid review was guided by a protocol (S1 Appendix) that was developed a priori by the authors and then reviewed by the guideline development group—a group of external experts who were invited by WHO to formulate recommendations regarding PPE use. The protocol allowed for modifications of scope and analysis during review conduct once the nature and volume of the evidence was known. We used the PRISMA reporting guideline for systematic reviews for the reporting of our work in this paper (S2 Appendix) [19].

The research question for this review was: what are the benefits and harms of double gloves, full face protection, head cover, impermeable gowns, particulate respirators, and rubber boots as PPE when compared with alternative and potentially less robust PPE for HCWs directly caring for patients with filovirus disease? Our lens for the review starts with the prevention of transmission to the HCW and subsequent transmission prevention from HCW to other patients.

**Eligibility criteria for studies**

We included studies of HCWs in health care facilities providing direct patient care to persons who had known or suspected filovirus disease (EVD or MVD) caused by any ebolavirus or marburgvirus. Health care facilities refers to both treatment centers specifically set up for managing filovirus disease (Ebola Treatment Centers), as well as to general health care treatment facilities such as health centers and hospitals.

We defined a list of PPE components and comparisons as a guide to identify relevant studies, but remained open to other comparisons if encountered in the literature (Fig 1).

Outcomes were specified by the guideline development group and included transmission of ebolavirus to HCWs and from HCWs to patients and adverse effects of using PPE such as perceived inconvenience or discomfort, injuries (e.g. needlestick injury), dexterity, reduced visibility, and heat-related events. Other outcomes in reports were also extracted.

As per our protocol, we first sought high quality systematic reviews, evidence-based clinical practice guidelines, and health technology assessments. In their absence, primary studies were retrieved using an evidence hierarchy: randomized controlled trials; quasi-experimental designs; comparative cohort, case-control studies, and cross-sectional studies, and in the event of no comparative evidence, we searched for and included data from non-comparative studies.

We considered studies published in either English or French published in 1967 (when filovirus disease first emerged) or later. No geographical restrictions were applied.

Because our initial search identified few publications, we expanded our search (as per our protocol) to include studies reporting on Crimean-Congo hemorrhagic fever or Lassa fever as
they were considered to have a similar mode of human-to-human transmission and infectivity to the filovirus diseases.

**Literature search**

Electronic search strategies were developed and tested iteratively by an experienced medical information specialist. Between 28 July and 7 August 2014, we searched Ovid MEDLINE and Ovid MEDLINE In-Process & Other Non-Indexed Citations, The Cochrane Database of Systematic Reviews (limited to the Cochrane Infectious Diseases Review Group reviews and specialized register), EMBASE, and African Index Medicus. Search strategies were not limited by language or year. A combination of controlled vocabulary and text-word terms were used ([S3 Appendix](#)), where possible. The initial MEDLINE search strategy was adapted to the other databases. Study design filters were applied.

Grey literature sources were searched on 20–22 August 2014 using the ProQuest Dissertations and Theses Databases and the Google Search Engine. We also searched ClinicalTrials.gov and WHO International Clinical Trials Registry Platform search portal to seek ongoing and completed trials. References of included studies were scanned. Acquisition of articles was focused to those available electronically through the research team’s institutional subscription; some full-text reports were sought elsewhere where time permitted.

**Study selection and data extraction**

De-duplicated citations in Reference Manager were uploaded to Distiller Systematic Review software for screening. Single reviewers assessed titles and abstracts with excluded records verified by a second reviewer. Any records with disagreements underwent full-text screening. Full-text reports were reviewed independently by two people, and disagreements between pairwise
reviewers were resolved by consensus or a third reviewer. Screening forms were pilot-tested using 15 (title/abstract) and 10 records (full text), respectively.

Single extractors collected information from studies, and a second person verified 57% of information. The extraction form was pilot-tested on nine included studies. Authors of included studies were not contacted for additional information due to time constraints.

Evidence Synthesis

Study characteristics are described narratively. Due to the nature and heterogeneity of included studies, meta-analysis of results was not done. Plots summarizing the proportion of HCWs reported to have experienced an outcome were produced where appropriate. The denominator included HCWs at risk for whom we knew the PPE worn.

Risk of bias assessments were not done due to the lack of validated instruments to assess the methodological quality of non-comparative designs [20].

Domains of the Grading of Recommendations Assessment Development and Evaluation (GRADE) framework were used to inform judgments on the quality of the evidence across studies for each outcome [21]. This framework initially considers evidence from observational studies as low quality and randomized controlled trials as high quality. Five domains related to quality are then assessed and used to determine the quality of the body of evidence for each outcome across studies: study limitations, consistency, directness, precision, and publication bias. Observational evidence without important threats to validity can be upgraded when there is a dose-response effect, a large magnitude of effect, or because plausible biases may have decreased the observed effect.

The study limitations domain addresses the risk of bias (internal validity) of studies [21]. Consistency addresses the degree to which studies yield similar results, while directness considers the degree to which the evidence aligns with the population, interventions, and outcomes of interest [22,23]. Precision judges the extent of random error by taking the sample size, number of observed events, and confidence intervals into consideration [24]. The publication bias domain addresses the degree to which published and unpublished studies yield systematically different findings [25].

Protocol modifications

We were able to increase the verification of extracted information from 10% to 57% of included studies.

Results

Identification of relevant studies

A total of 1,215 unique records were retrieved. No systematic reviews, evidence-based clinical practice guidelines or health technology assessment reports were identified. Furthermore, no comparative primary studies or ongoing trials were identified. However, 30 non-comparative studies [26–55] fulfilled the eligibility criteria (Fig 2). Ten of the 30 studies were identified through a scan of reference lists of included studies. A list of studies excluded following full-text review and reasons for exclusion are provided in S4 Appendix.

Characteristics of studies and study populations

The characteristics of studies reporting on gloves are provided in Fig 3. Studies reporting on other PPE combinations are summarized in S1–S16 Tables. Studies were published between 1969 and 2013 and conducted in Africa [26,27,32,33,36,38,39,49–53,55], Europe (including
Turkey) [30,31,34,35,37,42,43,47,48,54], South Asia and Western Asia [28,29,46], North America [40,41,45], and one study included HCWs in Africa and HCWs in Europe because of a patient repatriated to Europe [44].

Fig 2. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram of the study selection process.

doi:10.1371/journal.pone.0140290.g002
Eleven studies [26,27,32,35,36,39,49,50,54,55] reported on filoviruses, two on unspecified viral hemorrhagic fevers (VHF) [37,45], 11 on Crimean-Congo hemorrhagic fever [28–31,34,42–44,46,48,53], and six on Lassa fever [38,40,41,47,51,52]. Of the eight studies reporting on ebolavirus, three reported outbreaks of Sudan virus [32,33,55], four of Ebola virus [26,27,36,49], and one of Taï Forest virus [35].

While three studies were case reports of HCWs [34,46,54], a majority of studies involved contact tracing of HCWs providing care to index patients. Seven studies monitored HCWs for at least three weeks for outcomes, while others used a shorter follow-up, did not report this information, or did not actively follow participants.

Most studies examined nurses and physicians with or without other personnel providing patient care, including medical students, assistants, and other auxiliary staff members. Data from some studies included other personnel not providing direct patient care (e.g., laboratory workers, housekeeping staff, and administrative staff). Sample sizes were not consistently reported, and some studies reported the total number of contacts but did not specify the proportion of HCWs.

### Personal Protective Equipment

Only one study was designed with the intent to evaluate PPE use [30]. The PPE protocols varied across and within studies, i.e., over the duration of the care period or among HCWs. Several reports [27,36–39,41,49,50,55] described changes to the protocol, including delayed implementation of PPE or sequential introduction of PPE components during an outbreak. Three reports [29,38,44] traced HCW contacts from multiple health care facilities and described varying PPE protocols across the settings. A few studies reported varied adherence to the PPE protocol among HCWs within a given study [30,31,43] or only described the PPE used by a subset of HCW contacts (e.g., those who subsequently developed the disease) [27,28,34,46]. Three studies [33,42,50] reported adoption of established PPE guidelines for the management of patients with VHF including those developed by WHO and the Advisory Committee on Dangerous Pathogens.
Although we did not perform a formal assessment of the completeness of reporting across studies, our impression is that the reporting of PPE protocols was poor. In most reports, only a general description was provided of the components of PPE used without indication of the quality or specific characteristics (e.g., disposability, permeability, and other specifications). Further, important details including the quantity of each component used simultaneously by a single HCW (i.e., single or double gloves or gowns) was not reported. Some studies only partially reported the PPE protocol. For example, several studies specified one element of PPE (e.g., gloves, respirators, masks) but the remaining components were not described in detail (e.g., ‘protective clothing’, ‘barrier techniques’) [26,29,41,47,54].

Outcomes

Nearly all studies (90%; 27/30) reported on virus transmission from infected patients to HCWs. One study [45] reported no outcomes of interest as VHF was ruled out. Half of the studies measured virus transmission based on symptoms, serology and/or polymerase chain reaction (PCR) for at least a subset of HCWs [28–30,33,34,36,38–40,43,46,47,49–51,53,55]. The remaining studies used only symptoms [27,41,44,48,54], serologic or PCR/reverse transcription-PCR testing [31,35,52], or the method of ascertainment was not reported [26,32,37,42]. Three studies [30,31,52] reported on antibody prevalence among HCWs exposed to Crimean-Congo and Lassa fever virus.

The proportion of HCWs who experienced an event are presented (Figs 3–6, S1–S16 Tables), grouped by the combination of PPE elements worn. For filovirus disease, five of 11 studies reported virus transmission to HCWs having worn a variety of PPE combinations (Fig 4). One of those studies was unclear regarding timing of transmission (i.e., at what point during PPE protocol). Eight of 16 studies examining other types of VHF's reported viral transmission to HCWs having worn a various PPE combinations.

No studies reported on dexterity with the use of gloves or on adverse effects such as discomfort, reduced visibility, high temperatures, or humidity. Eight studies reported on needle stick injuries [29–31,34,37,43,53,54], one study on inadvertent touching of face with contaminated gloves [27], and one on glove perforation [29]. The proportion of HCWs with other outcomes (needle stick injury, glove perforation, and antibody prevalence) are shown in Figs 5 and 6.

Sources of Support

One study clearly indicated their sources of financial support [47]. Four studies indicated sources of support but did not provide the nature of the support [30,32,39,43]. Four studies listed the participation of organizations in providing or inferring outbreak support [27,33,49,55]. No companies manufacturing PPE components were listed among the involved organizations.

Discussion

In this rapid review, we identified 30 observational studies of PPE in the context of VHF's, of which 11 addressed filovirus disease. However, none of these studies compared different approaches to personal protection or different types of PPE. All studies included in this review, therefore, provide insufficient evidence on the comparative effectiveness of the different PPE protocols. Only one study was designed with the intent to evaluate PPE use [30]. Most reports involved contact tracing of HCWs providing care to index patients.

Using the GRADE framework, the quality of the body of evidence for all outcomes was assessed as very low. Despite the lack of validated instruments for evaluating the internal
| Virus/disease                  | Study partial citation | n   | N² | Proportion infected (n/N) | 95% CI         | Proportion infected and 95% CI |
|-------------------------------|------------------------|-----|----|---------------------------|----------------|-----------------------------|
| Gloves                       | Crimean-Congo          | 1   | 1  | 1·000                     | Not estimable  |                             |
|                              | Athar 2005             |     |    |                           |                |                             |
|                              | Altaf 1998             | 2   | 7  | 0·286                     | (0·072, 0·673)  |                             |
| Gloves, masks, gowns/aprons  | Filovirus              | 0   | 40 | 0·012                     | (0·001, 0·167)  |                             |
|                              | Formenty 1999          |     |    |                           |                |                             |
|                              | Shoemaker 2012         | 0   | 12 | 0·038                     | (0·002, 0·403)  |                             |
| Crimean-Congo                 | Papa 2002              | 0   | NR | Not estimable             |                |                             |
|                              | van de Wal 1985        | 0   | Unclear | Not estimable |                |                             |
|                              | Altaf 1998             | 0   | 21 | 0·023                     | (0·001, 0·277)  |                             |
| Lassa fever                   | Monath 1973            | 7   | 26 | 0·269                     | (0·134, 0·467)  |                             |
|                              | Helmick 1986           | 48  | 305| 0·157                     | (0·121, 0·203)  |                             |
|                              | Fisher-Hoch 1985       | 12  |    |                           |                |                             |
| Gloves, masks, gowns, glasses/goggles | Crimean-Congo | 0   | 21 | 0·024                     | (0·001, 0·287)  |                             |
| Gloves, mask or face shield, eye protection | Crimean-Congo | 0   |    |                           |                |                             |
| Gloves, masks, gowns, shoe covers | Filovirus | 0   | NR | Not estimable             |                |                             |
| Gloves, masks, gowns, caps, shoe covers | Lassa fever | 0   | 87 | 0·006                     | (0·000, 0·084)  |                             |
| Gloves, masks, gowns, respirators | Filovirus | 0   | 67 | 0·007                     | (0·000, 0·107)  |                             |
| Gloves, masks, gowns, goggles, respirators, caps | Filovirus | 230 |    | Not estimable             |                |                             |
| Gloves, masks, gowns, face visors, respirators, shoes | Unspecified VHF | 0   | 44 | 0·011                     | (0·001, 0·154)  |                             |
| Gloves, gowns, eye protection, respirators, boots | Filovirus | 1   | NR | Not estimable             |                |                             |
| Gloves, gowns, respirators or goggles+mask, scalp protection, shoe covers | Filovirus | 0   | 14 | 0·033                     | (0·002, 0·366)  |                             |
| Gloves and ‘barrier techniques’ (possibly including respirators) | Lassa fever | 0   |    | Not estimable             |                |                             |
| Gloves and ‘other equipment’ (not specified) | Lassa fever | 0   | 170| 0·003                     | (0·000, 0·045)  |                             |
| Protective clothing, respirators | Filovirus | 0   |    | Not estimable             |                |                             |
| WHO protocol (PPE not specified) | Filovirus | 5   | NR | Not estimable             |                |                             |
|                              | Borchart 2011          |     |    |                           |                |                             |
|                              | Gear 1975              | 1   | 35 | 0·029                     | (0·004, 0·177)  |                             |
| Advisory Committee on Dangerous Pathogens guidelines (PPE not specified) | Crimean-Congo | 0   | NR | Not estimable             |                |                             |
| ‘Standard precautions’ including masks | Crimean-Congo | 0   | 35 | 0·005                     | (0·000, 0·082)  |                             |

Fig 4. Virus transmission in non-comparative studies of healthcare workers wearing personal protective equipment. Abbreviations: CI = confidence interval; n = number of events; N = number of HCWs at risk for whom we knew the PPE worn; NR = not reported; WHO = World Health Organization. *Most studies did not provide data on all healthcare workers; only workers with available data were included. †Case reports: One report on filovirus (Martini 1969) and one on Crimean-Congo hemorrhagic fever (Naderi 2011) were identified. ‡One case report on Crimean-Congo hemorrhagic fever (Tutuncu 2009) was identified. §One case report on Crimean-Congo hemorrhagic fever (Naderi 2011) was identified. ¶PPE protocol was altered during process of care; unclear whether events occurred before or after the enhanced PPE protocol was implemented.

doi:10.1371/journal.pone.0140290.g004
validity of non-comparative studies, we can assume the literature to be at a high risk of bias. Given the body of evidence is non-comparative, this poses very serious limitations in terms of the directness of the evidence to the question of comparative effectiveness. The heterogeneity of the PPE components across and within studies over the duration of care and the heterogeneity of study designs limit the ability to assess the consistency of the data; most PPE combinations were reported by one study only. Estimates of the proportion of HCWs contracting the infection was generally based on small numbers and therefore imprecise. Publication bias could not be assessed quantitatively, and we do not know whether unpublished studies exist with systematically different findings.

| Virus/disease | Partial study citation | n  | N*    | Proportion with glove perforation (n/N) | 95% CI          | Proportion with outcome and 95% CI |
|---------------|------------------------|----|-------|----------------------------------------|-----------------|----------------------------------|
| Gloves        | Altaf 1998             | 2  | 7     | 0.286                                  | (0.072, 0.673)  |                                  |
|               |                        |    |       |                                        |                 |                                  |
| Gloves, masks, gowns/aprons | Gozel 2013         | 1  | 104   | 0.010                                  | (0.001, 0.065)  |                                  |
|               | Ergonul 2007           | 0  | 41    | 0.012                                  | (0.001, 0.164)  |                                  |
|               | van de Wal 1985        | 9  | Unclear | Not estimable                         |                 |                                  |
| Gloves, masks, gowns, face visors, shoes, respirators | Maltezou 2009   | 0  | 20    | 0.024                                  | (0.001, 0.287)  |                                  |
| Gloves, masks, gowns, glasses/goggles | Foberg 1991 | 3  | 44    | 0.068                                  | (0.022, 0.191)  |                                  |

Fig 5. Needle stick injury in non-comparative studies of healthcare workers wearing personal protective equipment. Abbreviations: CI = confidence interval; n = number of events; N = number of HCWs at risk for whom we knew the PPE worn. aMost studies did not provide data on all healthcare workers; only workers with available data were included. bOne case report on filovirus (Martini 1969) was also identified. cOne case report on Crimean-Congo hemorrhagic fever (Tutuncu 2009) was also identified.

Fig 6. Other adverse events in non-comparative studies of healthcare workers wearing personal protective equipment. Abbreviations: CI = confidence interval; n = number of events; N = number of HCWs at risk for whom we knew the PPE worn; NR = not reported; WHO = World Health Organization. aMost studies did not provide data on all healthcare workers; only workers with available data were included.
Only some of the studies monitoring a cohort of HCWs over a period of time did so for at least three weeks, the maximum incubation period described in the literature for filoviruses. Some cases of transmission may, therefore, have been missed. WHO recommends reverse transcriptase polymerase chain reaction (RT-PCR) or enzyme linked immunosorbent assay (ELISA) tests for the diagnosis of EVD, and we know at least some of the included studies incorporated these methods in the diagnostic work-up. However, a positive PCR test indicates the presence of viral particles which may or may not be infectious; therefore cell culture is needed for definitive diagnosis for EVD and MVD. Some of the studies relied solely on self-reported symptoms and temperature readings. Such studies are susceptible to bias as data on PPE was self-reported and, in a number of cases, retrospectively ascertained. In addition, it was unclear for many of the studies whether all HCWs in contact with patients were followed. It is possible that the proportion of HCWs infected were overestimated because those contracting EVD were probably more likely to be identified than those not contracting the disease.

When the PPE protocol was described, the reporting was poor and often lacked important details on the characteristics of the equipment (e.g., quality, disposability, permeability) and methods of donning and doffing. In some studies, outcomes could not be attributed to a particular PPE protocol because the PPE components were either not reported or poorly reported, or the protocol was altered during the process of care. The PPE worn by all exposed HCWs was not always adequately described. In some studies the recommended PPE was reported, while adherence was not. Lastly, determining the proportion of HCWs infected was often precluded by inadequate reporting of the sample size of exposed HCWs.

Two EVD studies postulated that transmission was due to protocol violations[33], including possible inadvertent touching of the face [27]. Where transmission was observed, it was difficult to attribute causation because of limitations of the observational studies included in this review, the possibility of other sources of transmission (for example, EVD cases in the community), and poor reporting. This was true even where needle stick injuries or glove perforations occurred as necessary details to definitively attribute causation (e.g., details and timing of PPE use) were not provided. Phylogenetic analyses can contribute to estimating the source of infection but such analyses were not done in the studies of HCWs included in this review.

Finally, it is important to consider that PPE is only one factor within the larger context of IPC. Other factors such as hand hygiene and environmental cleaning were beyond the scope of this review, but are critical elements in the development and implementation of IPC.

Strengths and limitations of the rapid review

This rapid review was guided by protocol developed \textit{a priori}. Although we limited the extent of bibliographic database searching, we searched African Index Medicus and grey literature sources to reduce the risk of location and publication biases. We used standard systematic approaches for study selection, data extraction, and synthesis. We also assessed the quality of the body of evidence using GRADE. Although intended as a rapid review, our work closely approximated that of a systematic review.

Limitations of our work stem from time constraints: search strategies were not peer-reviewed, we were unable to locate twelve full-text articles (S4 Appendix); and outcome extractions for 40% of studies were not verified by a second person.

Future research

Circumstances surrounding the ongoing EVD outbreak, including extremely challenging working conditions, scarce resources, population mobility, and deteriorated healthcare systems and infrastructures, make it difficult to collect data for inclusion in this review and possibly for
any future review update. However, efforts to collect data should be undertaken wherever possible. For example, comparative observational studies are needed to supplement the current evidence. Although case-control studies may be the most feasible, comparative cohort studies would be scientifically stronger. Further, randomized trials of the various components of PPE may be difficult to implement. More specifically, studies evaluating the current PPE protocols of organizations should be undertaken. For example, the WHO guidance released in on 31 October 2014 recommends the use of face shields or goggles for eye protection; however, empirical data comparing those forms of eye protection regarding transmissions and adverse effects (e.g., fogging, visibility) are currently not available.

Future research would benefit from standardized data collection instruments and population-based registries enabling synthesis of larger sample sizes. Also, an ongoing environmental scan of in-progress studies from various healthcare organizations providing service to African nations should be conducted. Although outside the scope of the rapid review, evidence is also needed for workers not providing direct clinical care.

Phylogenetic tracing should be performed where possible to estimate source of infection. Attention should also be given to collecting adverse outcomes of PPE use (e.g., inconvenience, discomfort, heat-related events, impaired dexterity, etc.).

Future studies need to be carefully and completely reported, using reporting guidelines such as CARE for clinical case reports, STROBE for observational studies, and CONSORT for randomized controlled trials. The use of such guidelines will facilitate adequate reporting and thus increase the usability of research reports, which will, in turn, facilitate decision making.

Another aspect of future research involves materials science and engineering. Technological advances to improve generally understood safety issues with PPE use, such as dexterity, comfort, and heat, and also to minimize the risk of contamination during the donning and doffing process while acting as a barrier to virus transmission during use would be ideal.

Implications for policy and practice

While we await better evidence to inform this topic, organizations and individuals need to consider how best to move forward with recommendations regarding PPE use. Although some may consider a zero-tolerance (100% effectiveness) approach, a number of reasons may preclude this as a strategy. First, we located no evidence that suggests totally impermeable materials are more effective than ‘only’ fluid-resistant materials for reducing virus transmission. Second, as mentioned earlier, a number of reasons may account for virus transmission, such as long working hours and transmission outside the patient care setting; WHO is in the process of finalizing an epidemiologic analysis of a subset of HCWs to better understand transmission cause. Although the adequacy of the PPE worn is important, correct donning and doffing of the equipment is an integral process for preventing infection [56]. There is general agreement as per knowledge and understanding among co-authors from this recent EVD outbreak that lack of adequate training on IPC, including donning and doffing, was an important factor for virus transmission. Further, a recent literature review identified inappropriate use of PPE and inadequate training as risk factors for HCW infections [57]. As a result, provision of training to HCWs in affected regions was identified as a “key strategy” for preventing ebolavirus transmission. In collaboration with other organizations responding to the ongoing EVD outbreak, WHO has developed job aids for HCWs on how to put on and remove PPE, and provided training on clinical management (including IPC measures) to over 4500 health responders on the ground in Guinea, Liberia, and Sierra Leone as of June 2015 [58,59]. Additional measures, such as ongoing guidance and monitoring of HCWs through the donning and doffing procedure, were also implemented in MSF Ebola treatment centers [56]. Readers can refer to WHO...
rapid advice guidance as an example of recommendations made by this organization following the completion of this rapid review [17].

**Conclusion**

Insufficient comparative evidence exists to draw conclusions regarding the effectiveness and harms of robust personal protective equipment compared with alternative, and potentially less robust personal protective equipment for healthcare workers providing direct patient care to those with filovirus disease.

**Supporting Information**

S1 Appendix. Rapid review protocol. (PDF)

S2 Appendix. Completed PRISMA checklist. (PDF)

S3 Appendix. Search strategy. (DOCX)

S4 Appendix. List of studies excluded during full-text screening. (DOCX)

S1 Table. Study characteristics table of non-comparative studies of healthcare workers wearing gloves. (DOCX)

S2 Table. Study characteristics table of non-comparative studies of healthcare workers wearing gloves, gowns/aprons, and masks. (DOCX)

S3 Table. Study characteristics of non-comparative studies of healthcare workers wearing gloves, mask or face shield, and eye protection. (DOCX)

S4 Table. Study characteristics of non-comparative studies of healthcare workers wearing gloves, masks, gowns, and shoe covers. (DOCX)

S5 Table. Study characteristics of non-comparative studies of healthcare workers wearing gloves, masks, gowns, caps, and shoe covers. (DOCX)

S6 Table. Study characteristics of non-comparative studies of healthcare workers wearing gloves, masks, gowns, and respirators. (DOCX)

S7 Table. Study characteristics of non-comparative studies of healthcare workers wearing gloves, masks, gowns, face visors, respirators, and shoes. (DOCX)

S8 Table. Study characteristics of non-comparative studies of healthcare workers wearing gloves, gowns, eye protection, respirators, and boots. (DOCX)
S9 Table. Study characteristics of non-comparative studies of healthcare workers wearing gloves, gowns, respirators or goggles plus mask, scalp protection, and shoe covers.

S10 Table. Study characteristics of non-comparative studies of healthcare workers wearing gloves, masks, gowns, goggles, respirators, and caps.

S11 Table. Study characteristics of non-comparative studies of healthcare workers wearing gloves and barrier techniques (possibly including respirators).

S12 Table. Study characteristics of non-comparative studies of healthcare workers wearing gowns and other equipment (not specified).

S13 Table. Study characteristics of non-comparative studies of healthcare workers wearing protective clothing and respirators.

S14 Table. Study characteristics of non-comparative studies of healthcare workers wearing PPE according to the WHO protocol.

S15 Table. Study characteristics of non-comparative studies of healthcare workers wearing PPE according to the Advisory Committee on Dangerous Pathogens guidelines.

S16 Table. Study characteristics of non-comparative studies of healthcare workers wearing PPE according to ‘standard precautions’ including masks.

Acknowledgments

We thank Benedetta Allegranzi, Yolanda Bayugo, Andreas Reis, Mikiko Senga as well as members of WHO Guideline Development Group (for WHO guideline on the PPE use by HCWs providing clinical care of patients with filovirus [EVD and MVD]) for providing input on the protocol. We are grateful to Tomas Allen, Raymond Daniel, and Dianne Wolfe for their assistance compiling this report. We thank Bill Cameron for his feedback on a draft version of this work.

Author Contributions

Wrote the paper: MH AS PQ CH KT CG BS CV SLN ME MF NS DM. Design of rapid review protocol: MH AS CG BS CV SLN ME SE NS DM. Data collection and analysis: MH AS PQ CH KT. Interpretation of evidence: MH AS PQ CH KT CG BS CV SLN ME SE MF NS DM.

References

1. King AMQ, Adams MJ, Carstens EB, Lefkowitz EJ. Virus Taxonomy: Classification and nomenclature of viruses. [Internet]. Available at: http://www.academia.edu/8097730/Ninth_Report_of_the_International_Committee_on_Taxonomy_of_Viruses. Accessed from: 11-9-2015.

2. Roddy P. A call to action to enhance filovirus disease outbreak preparedness and response. Viruses 2014 Oct; 6(10):3699–718. [PMID: 25271875] doi: 10.3390/v6103699
3. Towner JS, Amman BR, Sealy TK, Carroll SA, Comer JA, Kemp A, et al. Isolation of genetically diverse Marburg viruses from Egyptian fruit bats. PLoS Pathog 2009 Jul; 5(7):e1000536. [PMID: 19649327] doi: 10.1371/journal.ppat.1000536

4. Towner JS, Pourrut X, Albarino CG, Nkougne CN, Bird BH, Grand G, et al. Marburg virus infection detected in a common African bat. PLoS ONE 2007; 2(8):e764. [PMID: 17712412]

5. WHO Media centre. What we know about transmission of the Ebola virus among humans. [Internet]. Available at: http://www.who.int/mediacentre/news/ebola/06-october-2014/en/. Accessed from: 4-2-2015.

6. U.S. Centers for Disease Control and Prevention. Review of Human-to-Human Transmission of Ebola Virus. [Internet]. Available at: http://www.cdc.gov/vhf/ebola/transmission/human-transmission.html. Accessed from: 5-2-2015.

7. WHO Media centre. Ebola virus disease. [Internet]. Available at: http://www.who.int/mediacentre/factsheets/fs103/en/. Accessed from: 5-2-2015.

8. Baize S, Pannetier D, Oestereich L, Rieger T, Koivogui L, Magassouba N, et al. Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med 2014 Oct 9; 371(15):1418–25. [PMID: 24738641] doi: 10.1056/NEJMoa1404505

9. Curtis N. Viral haemorrhagic fevers caused by Lassa, Ebola and Marburg viruses. Adv Exp Med Biol 2006; 582:35–44. [PMID: 16802617]

10. World Health Organization. Ebola Situation Report—2 Sept 2015. [Internet]. Available at: http://apps.who.int/ebola/current-situation/ebola-situation-report-2-september-2015. Accessed from: 9-2-2015.

11. WHO Media centre. Unprecedented number of medical staff infected with Ebola. [Internet]. Available at: http://www.who.int/mediacentre/news/ebola/25-august-2014/en/. Accessed from: 20-11-2014.

12. WHO Media centre. Ebola virus disease in West Africa—the first 9 months of the epidemic and forward projections. N Engl J Med 2014 Oct 16; 371(16):1481–95. [PMID: 25244189] doi: 10.1056/NEJMoa1411100

13. Sterk, E. Filovirus Haemorrhagic Fever Guideline. [Internet]. Available at: http://www.medbox.org/ebola-guidelines/filovirus-haemorrhagic-fever-guideline/preview. Accessed from: 11-5-2015.

14. National Institute for Occupational Safety and Health (NIOSH). Workplace Safety & Health Topics. Heat Stress. [Internet]. Available at: http://www.cdc.gov/niosh/topics/heatstress/. Accessed from: 5-11-2015.

15. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines: 6. Rating the quality of evidence—imprecision. J Clin Epidemiol 2011 Dec; 64(12):1283–93. [PMID: 21839614] doi: 10.1016/j.jclinepi.2011.01.012

16. Guyatt GH, Oxman AD, Kunz R, Brozek J, Alonso-Coello P, Rind D, et al. GRADE guidelines: 5. Rating the quality of evidence—publication bias. J Clin Epidemiol 2011 Dec; 64(12):1277–82. [PMID: 21802904] doi: 10.1016/j.jclinepi.2011.01.011
Richards GA, Murphy S, Jobson R, Mer M, Zinman C, Taylor R, et al. Unexpected Ebola virus in a tertiary setting: clinical and epidemiologic aspects. Crit Care Med 2000 Jan; 28(1):240–4. [PMID: 10667531]

Khan AS, Tshioko FK, Heymann DL, Le GB, Nabeth P, Kerstiens B, et al. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995. Commission de Lutte contre les Epidemies a Kikwit. J Infect Dis 1999 Feb; 179 Suppl 1:S76–S86. [PMID: 9988168]

Athar MN, Khalid MA, Ahmad AM, Bashir N, Baqai HZ, Ahmad M, et al. Crimean-Congo hemorrhagic fever outbreak in Rawalpindi, Pakistan, February 2002: contact tracing and risk assessment. Am J Trop Med Hyg 2005 Apr; 72(4):471–3. [PMID: 15827289]

Altaf A, Luby S, Ahmed AJ, Zaidi N, Khan AJ, Mirza S, et al. Outbreak of Crimean-Congo hemorrhagic fever in Quetta, Pakistan: contact tracing and risk assessment. Trop Med Int Health 1998 Nov; 3 (11):878–82. [PMID: 9555399]

Ergonul O, Zeller H, Celikbas A, Dokuzoguz B. The lack of Crimean-Congo hemorrhagic fever virus antibodies in healthcare workers in an endemic region. Int J Infect Dis 2007; 11(1):48–51. PMID: 16600655

Shoemaker T, MacNeil A, Balinandi S, Campbell S, Wamala JF, McMullan LK, et al. Reemerging Sudan Ebola virus disease in Uganda, 2011. Emerg Infect Dis 2012 Sep; 18(9):1480–3. [PMID: 22931687]

Borchert M, Mutyaba I, Van Kerkhove MD, Lutwama J, Luwaga H, Bisoborwa G, et al. Ebola haemorrhagic fever outbreak in Masindi District, Uganda: outbreak description and lessons learned. BMC Infect Dis 2011; 11:357. [PMID: 21204600]

Tutuncu EE, Gurbuz Y, Ozturk B, Kuscu F, Sencan I. Crimean Congo haemorrhagic fever, precautions and ribavirin prophylaxis: a case report. Scand J Infect Dis 2009; 41(5):378–80. [PMID: 19343611] doi: 10.1080/00365540902882434

Formenty P, Hatz C, Le GB, Stoll A, Rogenmoser P, Widmer A. Human infection due to Ebola virus, subtype Cote d’Ivoire: clinical and biologic presentation. J Infect Dis 1999 Feb; 179 Suppl 1:S48–S53. [PMID: 9988164]

Kalangi Y, Mwanza K, Tshisuaka M, Lusiana N, Ntando E, Kanzake L, et al. Isolated case of Ebola hemorrhagic fever with mucormycosis complications, Kinshasa, Democratic Republic of the Congo. J Infect Dis 1999 Feb; 179 Suppl 1:S15–S17. [PMID: 9988159]

Foberg U, Fryden A, Isaksson B, Jahrling P, Johnson A, McKee K, et al. Viral haemorrhagic fever in Sweden: experiences from management of a case. Scand J Infect Dis 1991; 23(2):143–51. [PMID: 1853161]

Fisher-Hoch SP, Price ME, Craven RB, Price FM, Forthall DN, Sasso DR, et al. Safe intensive-care management of a severe case of Lassa fever with simple barrier nursing techniques. Lancet 1985 Nov 30; 2(8466):1227–9. [PMID: 2866301]

Smith DH, Johnson BK, Isaacson M, Swanapoel R, Johnson KM, Killey M, et al. Marburg-virus disease in Kenya. Lancet 1982 Apr 10; 1(8276):816–20. [PMID: 6122054]

Zweighaft RM, Fraser DW, Hattwick MA, Winkler WG, Jordan WC, Alter M, et al. Lassa fever: response to an imported case. N Engl J Med 1977 Oct 13; 297(15):803–7. [PMID: 895819]

Best EW. The Lassa fever episode, Metro Toronto, August, 1976. [French]. Can J Public Health 369 Sep; Revue Canadienne de Sante Publique. 67(5):361–6. [PMID: 991041]

Barr DA, Aitken C, Bell DJ, Brown CS, Croy J, Dawood N, et al. First confirmed case of Crimean-Congo haemorrhagic fever in the UK. The Lancet 2013; 382(9902):1458

Maltezou HC, Maltezos E, Papa A. Contact tracing and serosurvey among healthcare workers exposed to Crimean-Congo hemorrhagic fever in Greece. Scand J Infect Dis 2009; 41(11–12):877–80. [PMID: 19922073] doi: 10.3109/00365540903173619

Tarantola A, Nabeth P, Tattevin P, Michelet C, Zeller H. Lookback exercise with imported crimean-congo hemorrhagic fever, Senegal and France. Emerg Infect Dis 2006; 12(9):1424–6. [PMID: 17073094]

Loeb M, MacPherson D, Barton M, Olde J. Implementation of the Canadian contingency plan for a case of suspected viral hemorrhagic fever. Infect Control Hosp Epidemiol 2003; 24(4):280–3. PMID: 12725358

Naderi HR, Sarvghad MR, Bojdy A, Hadizadeh MR, Sadeghi R, Sheybani F. Nosocomial outbreak of Crimean-Congo hemorrhagic fever. Epidemiol Infect 2011 Jun; 139(6):862–6. [PMID: 20800007] doi: 10.1017/S0950268810002001
47. Haas WH, Breuer T, Pfaff G, Schmitz H, Kohler P, Asper M, et al. Imported Lassa fever in Germany: surveillance and management of contact persons. Clin Infect Dis 2003 May 15; 36(10):1254–8. [PMID: 12746770]

48. Papa A, Bozovi B, Pavlidou V, Papadimitriou E, Pelonis M, Antoniadis A. Genetic detection and isolation of crimean-congo hemorrhagic fever virus, Kosovo, Yugoslavia. Emerg Infect Dis 2002 Aug; 8(8):852–4. [PMID: 12141973]

49. Ebola haemorrhagic fever in Zaire, 1976. Bull World Health Organ 1978; 56(2):271–93. [PMID: 307456]

50. Gear JS, Cassel GA, Gear AJ, Trapper B, Clausen L, Meyers AM, et al. Outbreak of Marburg virus disease in Johannesburg. Br Med J 1975 Nov 29; 4(5995):489–93. [PMID: 811315]

51. Monath TP, Mertens PE, Patton R, Moser CR, Baum JJ, Pinneo L, et al. A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972. Am J Trop Med Hyg 1973 Nov; 22(6):773–9. [PMID: 4745236]

52. Helmick CG, Webb PA, Scribner CL, Krebs JW, McCormick JB. No evidence for increased risk of Lassa fever infection in hospital staff. Lancet 1986 Nov 22; 2(8517):1202–5. [PMID: 2877335]

53. van de Wal BW, Joubert JR, van Eeden PJ, King JB. A nosocomial outbreak of Crimean-Congo hemorrhagic fever at Tygerberg Hospital. Part IV. Preventive and prophylactic measures. S Afr Med J 1985 Nov 9; 68(10):729–32. [PMID: 2414853]

54. Martini GA. Marburg agent disease: in man. Trans R Soc Trop Med Hyg 1969; 63(3):295–302. [PMID: 5815873]

55. Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull World Health Organ 1978; 56(2):247–70. [PMID: 307455]

56. Fischer WA, Hynes NA, Perl TM. Protecting health care workers from Ebola: personal protective equipment is critical but is not enough. Ann Intern Med 2014 Nov 18; 161(10):753–4. [PMID: 25155746] doi: 10.7326/M14-1953

57. World Health Organization. Health worker Ebola infections in Guinea, Liberia and Sierra Leone. [Internet]. Available at: http://apps.who.int/iris/bitstream/10665/171823/1/WHO_EVD_SDS_REPORT_2015.1_eng.pdf?ua=1&ua=1. Accessed from: 11-9-2015.

58. World Health Organization. How to put on and how to remove personal protective equipment—posters. [Internet]. Available at: http://www.who.int/csr/resources/publications/ebola/ppe-steps/en/. Accessed from: 17-9-2015.

59. World Health Organization. Ebola Response in Action. [Internet]. Available at: http://apps.who.int/ebola/our-work/achievements. Accessed from: 17-9-2015.